Drug Search Results
More Filters [+]

Ralimetinib

Alternative Names: ralimetinib, ly2228820
Latest Update: 2024-02-16
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ralimetinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Breast Cancer|Glioblastoma

Phase 1: Oncology Unspecified|Non-Small-Cell Lung Cancer|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GLYRad

P2

Completed

Glioblastoma

2019-08-01

I1D-MC-JIAE

P2

Completed

Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer

2017-05-25

I4D-MC-JTJL

P1

Completed

Colorectal Cancer|Non-Small-Cell Lung Cancer

2017-05-15

OLYMPE

P2

Terminated

Breast Cancer

2017-04-01

Recent News Events